Costs and Spillover Effects of Private Insurers' Coverage of Hepatitis C Treatment
Expanding private-payer coverage of hepatitis C treatment may yield significant long-term cost savings for private payers, reduced costs to Medicare, and increased social value.
Value of Expanding HCV Screening and Treatment Policies in the United States
Expanding screening for hepatitis C virus infection may generate substantial benefits for patients and society, but only when paired with expanded treatment policies.
Does Patient Cost Sharing for HCV Drugs Make Sense?
Despite the high cost of novel hepatitis C treatments and patients' apparent willingness to bear part of it, high patient cost sharing is both inefficient and inequitable.
